Active substance
Results for the substance datopotamab deruxtecan
1 result
About this active substance
Datopotamab deruxtecan combines an anti-TROP2 antibody with a cell-killing medicine delivered into tumour cells. It treats adults with inoperable or metastatic HR-positive, HER2-negative breast cancer after endocrine therapy and chemotherapy. In the USA, it is also approved for selected patients with triple-negative breast cancer or EGFR-mutated lung cancer.
It is given by intravenous infusion, usually every 3 weeks, in an oncology centre. The dose depends on weight and tolerability. The team recommends anti-sickness medicines, a steroid mouthwash and preservative-free lubricating eye drops. Attend eye examinations and do not wear contact lenses without the specialist's agreement.
Side effects include painful mouth ulcers, nausea, vomiting, tiredness, hair loss, constipation and dry eyes. Corneal inflammation, changes in blood tests and infusion reactions may occur. The medicine can cause severe, sometimes fatal non-infectious lung inflammation.
Tell the oncology team immediately about a new cough, breathlessness, fever, eye pain, altered vision or mouth sores that prevent eating. The doctor may delay a dose, reduce it or stop treatment. Avoid pregnancy and breastfeeding; continue contraception after the last dose for the recommended period. This medicine is not interchangeable with trastuzumab deruxtecan.
It is given by intravenous infusion, usually every 3 weeks, in an oncology centre. The dose depends on weight and tolerability. The team recommends anti-sickness medicines, a steroid mouthwash and preservative-free lubricating eye drops. Attend eye examinations and do not wear contact lenses without the specialist's agreement.
Side effects include painful mouth ulcers, nausea, vomiting, tiredness, hair loss, constipation and dry eyes. Corneal inflammation, changes in blood tests and infusion reactions may occur. The medicine can cause severe, sometimes fatal non-infectious lung inflammation.
Tell the oncology team immediately about a new cough, breathlessness, fever, eye pain, altered vision or mouth sores that prevent eating. The doctor may delay a dose, reduce it or stop treatment. Avoid pregnancy and breastfeeding; continue contraception after the last dose for the recommended period. This medicine is not interchangeable with trastuzumab deruxtecan.